文献速递核素与放射性配体治疗

单次剂量211At标记抗HER2单域抗体片段有效治疗人乳腺癌异种移植瘤

Effective Treatment of Human Breast Carcinoma Xenografts with Single-Dose 211At-Labeled Anti-HER2 Single-Domain Antibody Fragment.
PubMed 文献 · J Nucl Med · 2022-05-26

研究评估了两种结合HER2结构域IV的高亲和力单域抗体片段(5F7和VHH_1028-2)经iso-211At-SAGMB标记后的靶向α粒子治疗潜力。在BT474乳腺癌细胞中,iso-211At-SAGMB-5F7降低克隆存活(D0=1.313 kBq/mL),而对照抗体无效。小鼠皮下BT474异种移植瘤实验中,3.0 MBq剂量下iso-211At-SAGMB-5F7组4只中3只、iso-211At-SAGMB-VHH_1028组11只中8只获完全肿瘤消退,中位生存期分别延长495%和414%。

要点

  • iso-211At-SAGMB-5F7在BT474细胞中降低克隆存活,D0=1.313 kBq/mL,对照抗体无效。
  • 3.0 MBq单次剂量下,5F7组4只中3只、VHH_1028组11只中8只完全肿瘤消退。
  • 中位生存期延长:5F7组495%,VHH_1028组414%。

核心结论

  • 将快速内化、高亲和力的HER2靶向单域抗体片段与iso-211At-SAGMB残余化 prosthetic 剂结合,是HER2表达癌症靶向α粒子治疗的有前景策略。

研究设计与样本

  • 研究使用5F7和VHH_1028-2两种结合HER2结构域IV的高亲和力单域抗体片段,以及HER2无关的VHH_2001对照,经iso-211At-SAGMB标记。
  • 在HER2表达的BT474乳腺癌细胞中比较iso-211At-SAGMB-5F7与iso-211At-SAGMB-VHH_2001的细胞毒性。
  • 在小鼠皮下BT474异种移植瘤中开展三项实验,评估单次剂量iso-211At-SAGMB-5F7(0.7-3.0 MBq)、iso-211At-SAGMB-VHH_1028(1.0-3.0 MBq)及iso-211At-SAGMB-VHH_1028与iso-211At-SAGMB-VHH_2001(约1.0 MBq)的治疗效果。

主要发现

  • BT474细胞暴露于iso-211At-SAGMB-5F7后克隆存活降低(D0=1.313 kBq/mL),而iso-211At-SAGMB-VHH_2001无效。
  • 211At标记的HER2特异性5F7和VHH_1028观察到剂量依赖性肿瘤生长抑制,而HER2无关的VHH_2001无此效果。
  • 3.0 MBq剂量下,iso-211At-SAGMB-5F7组4只小鼠中3只完全肿瘤消退,iso-211At-SAGMB-VHH_1028组11只中8只完全肿瘤消退。
  • 中位生存期延长分别为495%(5F7组)和414%(VHH_1028组)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Single-domain antibody fragments (sdAbs) are attractive for targeted α-particle therapy, particularly with 211At, because of their rapid accumulation in tumor and clearance from normal tissues. Here, we evaluate the therapeutic potential of this strategy with 5F7 and VHH_1028-2 sdAbs that bind with high affinity to domain IV of human epidermal growth factor receptor type 2 (HER2). Methods: The HER2-specific sdAbs and HER2-irrelevant VHH_2001 were labeled using N-succinimidyl-3-211At-astato-5-guanidinomethyl benzoate (iso-211At-SAGMB). The cytotoxicity of iso- 211At-SAGMB-5F7 and iso- 211At-SAGMB-VHH_2001 were compared on HER2-expressing BT474 breast carcinoma cells. Three experiments in mice with subcutaneous BT474 xenografts were performed to evaluate the therapeutic effectiveness of single doses of iso- 211At-SAGMB-5F7 (0.7-3.0 MBq), iso- 211At-SAGMB-VHH_1028 (1.0-3.0 MBq), and iso- 211At-SAGMB-VHH_1028 and iso- 211At-SAGMB-VHH_2001 (∼1.0 MBq). Results: Clonogenic survival of BT474 cells was reduced after exposure to iso- 211At-SAGMB-5F7 (D0 = 1.313 kBq/mL) whereas iso- 211At-SAGMB-VHH_2001 was ineffective. Dose-dependent tumor growth inhibition was observed with 211At-labeled HER2-specific 5F7 and VHH_1028 but not with HER2-irrelevant VHH_2001. At the 3.0-MBq dose, complete tumor regression was seen in 3 of 4 mice treated with iso- 211At-SAGMB-5F7 and 8 of 11 mice treated with iso- 211At-SAGMB-VHH_1028; prolongation in median survival was 495% and 414%, respectively. Conclusion: Combining rapidly internalizing, high-affinity HER2-targeted sdAbs with the iso- 211At-SAGMB residualizing prosthetic agent is a promising strategy for targeted α-particle therapy of HER2-expressing cancers.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Feng Y, Meshaw R, Zhao XG, et al. Effective Treatment of Human Breast Carcinoma Xenografts with Single-Dose 211At-Labeled Anti-HER2 Single-Domain Antibody Fragment. J Nucl Med. 2022. PMID: 35618478. doi:10.2967/jnumed.122.264071

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。